NEXO
12.3.2024 17:26:34 CET | Business Wire | Press release
20+ leading crypto organizations including BTC Inc, Bitget, Brink, Chainalysis, Hacken, Nansen, and Unstoppable Domains have come together for the 'Bitcoin Deserves an Emoji' movement, initiated by Nexo. Uniting the global crypto community, the initiative aims to introduce a Bitcoin emoji to any digital keyboard and emphasize cryptocurrency's triple identity as money, technology, and culture in today’s society.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312299831/en/
Uniting the global crypto community, the 'Bitcoin Deserves an Emoji' initiative aims to introduce a Bitcoin emoji to any digital keyboard and emphasize cryptocurrency's triple identity as money, technology, and culture in today’s society. (Graphic: Business Wire)
This community-driven initiative starts with a 50-day petition on Change.org, followed by an official proposal to the Unicode Consortium during the 2024 submission window. The new, widespread effort for a Bitcoin emoji, once turned down in 2020, shows just how important blockchain has become in our daily lives.
Celebrating Community, Culture, and Collective Values
92% of internet users worldwide use emojis in their digital communications, according to Unicode. Originating in Japan in the 1990s, emojis have transformed from niche pictographs to key elements of online conversations, transcending language and borders to reflect our values, innovations, and contemporary culture. Similarly, Bitcoin, beyond being a mere asset, displays the technological breakthrough of blockchain, embodying principles of decentralization, transparency, and security. Its inclusion as an emoji would not only symbolize its indispensable role in today's digital and financial landscapes but also ensure Bitcoin is recognized as an integral part of daily life across the globe.
Voices of the Movement
Already gaining substantial traction, the Bitcoin Emoji Initiative showcases the unity within the cryptocurrency community and the shared goal of further establishing Bitcoin's presence in our cultural landscape.
“Bitcoin's journey reflects a remarkable blend of innovation and community. It's time its significance is recognized universally, starting with a symbol we all understand - an emoji. Join us in making history,” said Kosta Kantchev, Co-founder & Executive Chairman of Nexo.
“Bitcoin is universal money for the world, it needs a universal emoji for every person, young and old to use,” said David Bailey, CEO of BTC Inc.
“Supporting Bitcoin's development has always been about changing the world through code. An official emoji is a nod to Bitcoin's technological impact on the world.” said Mike Schmidt, Executive Director of Brink.
"Bitget recognizes the significance of having a Bitcoin emoji as a universal symbol of digital assets in our everyday communication. This initiative aligns with our mission to promote crypto adoption and accessibility. We wholeheartedly support this endeavor and believe it will contribute further to mainstream acceptance of the whole industry. Together with our partners and the wider crypto community, we are committed to advocating for the inclusion of a Bitcoin emoji on keyboards worldwide,” said Gracy Chen, Managing Director of Bitget.
"We fully support Nexo's petition as this initiative to create a Bitcoin Emoji aligns perfectly with Nansen's commitment to fostering a more inclusive and expressive crypto environment”, said Alex Svanevik, CEO and co-founder of Nansen.
“For a decade, Chainalysis has been dedicated to fostering trust in blockchains while aiding the advancement of the web3 ecosystem and assisting public sector entities in staying abreast of crypto developments. As a trailblazer in blockchain analysis, we've safeguarded and championed Bitcoin since its inception. We commend Nexo's advocacy for acknowledging a cultural symbol—the Bitcoin emoji—a testament to the era we inhabit”, said Ian Andrews, CMO of Chainalysis.
"The definition of an emoji is a small digital image or icon used to express an idea. Bitcoin is now a well-known idea across all countries. CryptoQuant fully supports Nexo's initiative to facilitate the global mass adoption of Bitcoin," said CryptoQuant's CEO Ki Young Ju.
“The Bitcoin emoji reflects the essence of decentralization, representing a collective movement towards a more open and inclusive financial future for everyone. We align with Nexo's Bitcoin Emoji petition,” said Sam Lekhak, Head of Marketing & Comms at Liquity.
“We're thrilled to stand alongside industry leaders in championing a Bitcoin emoji, a move poised to give identity to the industry while also serving as a bridge between technical innovation and cultural expression,” said Sandy Carter, COO, Unstoppable Domains
Join the Movement
Everyone is invited to be part of this historic community-driven initiative. By signing the Change.org petition and advocating for the Bitcoin emoji, everyone can contribute to celebrating Bitcoin's legacy and future. For more information and to join the campaign, visit bitcoinemoji.org.
About the Initiative
This initiative is a collaborative effort by 20+ leading organizations in the cryptocurrency space, united by a common goal to promote understanding, adoption, and technological progress of digital currencies. Participating organizations: Nexo, Brink, Bitget, Chainalysis, Polygon, Brave, BTC Inc, Hacken, CryptoQuant, Nansen, Unstoppable Domains, Liquity, Mara, Busha, Zulu, Cadenza, Bware Labs, Meta4 Capital, Sift, MarketAcross, Bitcompare, Bithomp, Milkroad, Crypto Oasis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312299831/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom